China's National Healthcare Security Administration (NHSA) on December 7 unveiled the updated national reimbursement drug list, securing coverage for five independently developed innovative drugs from Zhongshan-based company Akeso Inc after successful price negotiations. All approved indications for these drugs are now fully covered under the medical insurance scheme.

The newly listed therapies address multiple disease areas including cancer, psoriasis and hyperlipidemia, delivering optimized non-chemotherapy treatment options for patients while significantly reducing financial burdens associated with care.